



MO HEALTHNET PHARMACY PROGRAM NEW DRUGS AND EDITS WITH NO ANNUAL CHANGES

**MHD PA COMMITTEE SEPTEMBER 16, 2021
JOSH MOORE, PHARM D – DIRECTOR OF PHARMACY**

NEW DRUGS – CLINICAL EDITS

Common Trade Name	Ingredient Name	Indications
Abecma 460X10EXP6 Infusion Bag	Idecabtagene Vicleucel	Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. CAR T Cell Clinical Edit
Aduhelm 170mg/1.7ml Vial Aduhelm 300mg/3ml Vial	Aducanumab-Avwa	Indicated for the treatment of Alzheimer’s disease. Aduhelm Clinical Edit * New edit to be discussed today

NEW DRUGS – CLINICAL EDITS

Common Trade Name	Ingredient Name	Indications
Empaveli 1,080mg/20ml Vial	Pegcetacoplan	Indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Clinical Review for Medical Necessity
Methadone HCL 5mg/0.5ml Oral Syringe	Methadone HCL	Indicated for: <ul style="list-style-type: none"> • Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). • Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Opioids, Short Acting Clinical Edit
Myfembree 40mg-1mg-0.5mg Tablet	Relugolix/Estradiol/Norethindr	Indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Elagolix Clinical Edit
Nulibry 9.5mg Vial	Fosdenopterin Hydrobromide	Indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. Nulibry Clinical Edit
Trikafta 50-25-37.5mg/75mg Tablet	Elexacaftor/Tezacaftor/Ivacaft	Indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit
Xcopri 250mg Tablet	Cenobamate	Indicated for the treatment of partial-onset seizures in adult patients. Xcopri Clinical Edit

NEW DRUGS – PDL EDITS

Common Trade Name	Ingredient Name	Indications
Barhemsys 5mg/2ml Vial	Amisulpride	<p>Indicated in adults for:</p> <ul style="list-style-type: none"> • Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. • Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. <p>Antiemetic 5-HT₃, NK1 and Other Select Agents PDL - Non-Preferred</p>
Cosentyx 75mg/0.5ml Syringe	Secukinumab	<p>Indicated for the treatment of:</p> <ul style="list-style-type: none"> • moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy • adults with active psoriatic arthritis (PsA) • adults with active ankylosing spondylitis (AS) • adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation <p>Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors PDL - Non-Preferred</p>
Dupixent 200mg/1.14ml Pen	Dupilumab	<p>Indicated:</p> <ul style="list-style-type: none"> • for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. • as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. • as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). <p>Respiratory Monoclonal Antibodies (RMA) PDL - Non-Preferred</p>
Gemtesa 75mg Tablet	Vibegron	<p>Indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.</p> <p>Urinary Tract Antispasmodics PDL Edit - Non-Preferred</p>

NEW DRUGS – PDL EDITS

Common Trade Name	Ingredient Name	Indications
Ingrezza 60mg Capsule	Valbenazine Tosylate	Indicated for the treatment of adults with tardive dyskinesia. VMAT2 Inhibitors PDL - Non-Preferred
Ozobax 5mg/5ml Solution	Baclofen	Indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Skeletal Muscle Relaxants PDL Edit - Non-Preferred Approve for children < 10 years of age without a trial of a preferred agent.
Pancreaze DR 2,600u Capsule Pancreaze DR 37,000u Capsule	Lipase/Protease/Amylase	Indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Pancreatic Enzymes PDL - Non-Preferred
Qdolo 5mg/ml Solution	Tramadol HCl	Indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Tramadol-Like Agents PDL Edit - Non-Preferred
Qelbree ER 100mg Capsule Qelbree ER 150mg Capsule Qelbree ER 200mg Capsule	Viloxazine HCl	Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. ADHD, Non-Stimulants PDL - Non-Preferred * Edit to be discussed today
Reltone 200mg Capsule Reltone 400mg Capsule	Ursodiol	Indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Bile Salt Agents PDL - Non-Preferred

NEW DRUGS – PDL EDITS

Common Trade Name	Ingredient Name	Indications
Skyrizi 150mg/ml Pen Skyrizi 150mg/ml Syringe	Risankizumab-Rzaa	Indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors PDL - Non-Preferred
Zegalogue 0.6mg/0.6ml Syringe Zegalogue 0.6mg/0.6ml Auto Injector	Dasiglucagon HCl	Indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. Hypoglycemia Agents PDL - Non-Preferred

NEW DRUGS – OPEN ACCESS

Common Trade Name	Ingredient Name	Indications
Definity RT 0.65mg/ml Vial	Perflutren Lipid Microspheres	Indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
Elepsia XR 1,000mg Tablet Elepsia XR 1,500mg Tablet	Levetiracetam	Indicated as adjunctive therapy for the treatment of partial-onset seizures in patients 12 years of age and older.
Fluorescein-Benoxinate 0.3%-0.4% Drops	Benoxinate HCl/Fluorescein Sod	Indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.
Hematogen 66-250-10 Softgel	Ferrous Fumarate/Vit C/Vit B12	For the treatment of all anemias responsive to oral iron therapy, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary restriction, metabolic disease and post-surgical convalescence.
Nextstellis 3mg-14.2mg Tablet	Drospirenone/Estetrol	Indicated for use by females of reproductive potential to prevent pregnancy.
Regen-Cov 600-600mg/10ml Vial	Casirivimab/Imdevimab	For the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Sotrovimab (EUA) 500mg/8ml Vial	Sotrovimab	For the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Zynrelef 200-6mg/7ml Vial Zynrelef 400-12mg/14ml Vial	Bupivacaine/Meloxicam	Indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.

NEW DRUGS – PA CONTINUED

Common Trade Name	Ingredient Name	Indications
Exservan 50mg Film	Riluzole	Indicated for the treatment of amyotrophic lateral sclerosis (ALS). Criteria: Must use 50 mg tabs unless there are swallowing issues that would necessitate use of oral films.

CLINICAL & FISCAL EDITS WITH NO ANNUAL CHANGES

- ▶ Emsam
- ▶ Immunoglobulin
- ▶ Lambert-Eaton Myasthenic Syndrome (LEMS)
- ▶ Neuromyelitis Optica Spectrum Disorder (NMOSD)
- ▶ Nuedexta
- ▶ Oxandrin
- ▶ Palforzia
- ▶ Ranexa
- ▶ Transthyretin-Mediated Amyloidosis (ATTR)
- ▶ Xcopri

PREFERRED DRUG LIST EDITS WITH NO ANNUAL CHANGES

- ▶ ARBs and ARBs/Diuretic Combinations
- ▶ ARBs/CCB Combinations
- ▶ Beta Blockers and Beta Blockers/Diuretic Combinations
- ▶ Calcium Channel Blockers, Dihydropyridine
- ▶ Calcium Channel Blockers, Non-Dihydropyridine
- ▶ Direct Renin Inhibitors and Combinations
- ▶ Dry Eye Disease Agents
- ▶ Niacin Derivatives
- ▶ PAH, ETRAs
- ▶ PAH, Prostacyclins Inhaled
- ▶ PAH, Prostacyclins Oral
- ▶ Sympatholytics